Abu Dhabi - Mubasher: The net profits of Gulf Pharmaceutical Industries (Julphar) hit AED 175.30 million in 2025, reflecting higher year-on-year (YoY) results compared with AED 35 million.
The earnings per share (EPS) amounted to 0.15 fils as of 31 December 2025 when compared with a loss per share of 0.01 fils in 2024, according to the income statement.
Revenues from continuing operations hiked to AED 1.05 billion in the January-December 2025 period from AED 992.20 million in 2024.
Furthermore, the ADX-listed company posted YoY lower total assets at AED 1.81 billion in 2025, compared with AED 2.45 billion.
The company stated: “These results highlight our continued progress in maintaining a strong balance between investments, a solid capital structure, and sustainable long-term shareholder value creation."
“Our strong market position continues to be reinforced by the dedication and commitment of our teams across all operating regions,” Julphar added.
